Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01552447 · ClinicalTrials.gov registry record · NA

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

A NA study of Venous Leg Ulcer, sponsored by MiMedx Group.

Completed
Registry status
NA
Development phase
98
Enrollment target
5
Study locations

NCT01552447: Completed NA study of Venous Leg Ulcer, sponsored by MiMedx Group.

NCT01552447 is a NA study of Venous Leg Ulcer that has completed, run by MiMedx Group. The registered enrollment target is 98 participants, below the 242-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (60% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01552447, a NA study of Venous Leg Ulcer, has completed, sponsored by MiMedx Group.

COMPLETED
Registry status
NA
Development phase
98 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of venous leg ulcers.

Conditions Studied

Interventions

  • OTHER EpiFix
  • OTHER Compression Therapy

Study Locations (5)

Pennsylvania

  • St. Vincent's Health Center - Erie
  • Armstrong County Memorial Hospital - Kittanning

Florida

  • Eric J. Lullove DPM - Boca Raton

Massachusetts

  • MetroWest Medical Center - Framingham

Oklahoma

  • St. Johns Wound Center - Tulsa

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2012-03
Est. Completion 2014-05
Phase NA
MiMedx Group

32 total trials

What the finished NCT01552447 record still lists

NCT01552447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 242-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (60% lower).

The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 2 interventions - of which EpiFix is the first listed.

NCT01552447 lists 5 locations in 4 states (Pennsylvania, Florida, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT01552447 about?

NCT01552447 is a clinical study titled "Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers". The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of venous leg ulcers.

What is the current status of trial NCT01552447?

This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2012-03. Estimated completion is 2014-05.

What conditions does trial NCT01552447 study?

This clinical trial studies the following conditions: Venous Leg Ulcer.

What interventions are being tested in trial NCT01552447?

The interventions under investigation include: EpiFix (OTHER), Compression Therapy (OTHER).

Who is sponsoring clinical trial NCT01552447?

This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01552447 being conducted?

This trial has 5 study locations across Florida, Massachusetts, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Leg Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01552447's enrollment target sits among peer trials

98 25th of 35 higher than 11 of 35 other Venous Leg Ulcer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Venous Leg Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02926729 · 98 participants · NA

    Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy

  • NCT03382977 · 98 participants · Phase 1

    Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

  • NCT04577014 · 98 participants · Phase 1

    Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

  • NCT04817618 · 98 participants · Phase 3

    Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01552447, the US trial registry maintained by the National Library of Medicine. NCT01552447 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.